Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOSIG TECHNOLOGIES, INC.

(BSGM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Certain Series C Preferred Stock of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2021.

10/01/2021 EST

Certain Series C Preferred Stock of BioSig Technologies, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2021. These Series C Preferred Stock will be under lockup for 91 days starting from 2-JUL-2021 to 1-OCT-2021. Details: The executive officers, directors and certain of the stockholders have entered into lock-up agreements with the underwriters pursuant to which each of these persons or entities, with limited exceptions, may not, directly or indirectly, without the prior written consent of Laidlaw & Company (UK) Ltd.: (1) offer for sale, sell, contract to sell, pledge, or otherwise dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future of), directly or indirectly, any shares of common stock (including, without limitation, shares of common stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and shares of common stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for common stock, for a period of 90 days after the date of the final prospectus supplement for this offering.


ę S&P Capital IQ 2021
All news about BIOSIG TECHNOLOGIES, INC.
12/01BIOSIG TECHNOLOGIES : Seasoned electrophysiology sales executive joins the Company to expa..
PU
12/01BIOSIG TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
12/01BioSig Technologies, Inc. Appoints Gray Fleming as Chief Commercial Officer
AQ
12/01BioSig Technologies, Inc. Appoints Gray Fleming as Chief Commercial Officer
CI
11/17BioSig to Participate in the The Benchmark Company 10th Annual Discovery Conference
AQ
11/16BIOSIG TECHNOLOGIES : Company partners with the leading academic institution on research a..
PU
11/16BIOSIG TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
11/16BioSig Technologies Starts Artificial Intelligence Project with Israel's Technion; Shar..
MT
11/16BioSig Initiates Artificial Intelligence Development Program with Technion – Isra..
AQ
11/15Note 2 - management's liquidity plans
AQ
More news
Financials (USD)
Sales 2021 1,04 M - -
Net income 2021 -31,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,71x
Yield 2021 -
Capitalization 92,9 M 92,9 M -
Capi. / Sales 2021 89,3x
Capi. / Sales 2022 7,11x
Nbr of Employees 49
Free-Float 86,9%
Chart BIOSIG TECHNOLOGIES, INC.
Duration : Period :
BioSig Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOSIG TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,63 $
Average target price 13,00 $
Spread / Average Target 394%
EPS Revisions
Managers and Directors
Kenneth L. Londoner Executive Chairman & Chief Executive Officer
Steven Chaussy Chief Financial Officer
Budimir S. Drakulic Chief Scientist
Barry Keenan Vice President-Engineering
Julie Stephenson Vice President-Clinical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOSIG TECHNOLOGIES, INC.-32.82%93
THERMO FISHER SCIENTIFIC36.57%250 658
DANAHER CORPORATION40.88%223 620
INTUITIVE SURGICAL, INC.20.03%114 898
SIEMENS HEALTHINEERS AG52.50%80 761
EDWARDS LIFESCIENCES CORPORATION20.38%67 728